Strumento inattivo

Altre lingue Miragen Therapeutics Inc Nasdaq

Azioni

US8266402036

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

11/06	Aggiornamento settoriale: i titoli del settore sanitario sono stati misti martedì prima del mercato	MT
11/06	Aggiornamento settoriale: Assistenza sanitaria	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	04/07
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/07
Sector Update: Health Care Stocks Mixed Premarket Tuesday	11/06
Sector Update: Health Care	11/06
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as US FOMC Meeting Begins	11/06
Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket	11/06
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease	11/06
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-To-Severe Thyroid Eye Disease	11/06
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	07/06
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/06
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences	31/05
Viridian Therapeutics to Participate in Upcoming May Investor Conferences	13/05
Viridian Therapeutics to Participate in Upcoming May Investor Conferences	10/05
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q1 Revenue $72,000	08/05
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results	08/05
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	06/05
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024	29/04
Foghorn Therapeutics Names Kristian Humer CFO	16/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Miragen Therapeutics Inc Nasdaq

Azioni

US8266402036

Altre lingue

Filtri